Arina Koroleva

Arina Koroleva

Auto-generated profile, based on publicly available information

Arina Koroleva

University of Turku

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 July 2022 in Metabolic Engineering
Verified
Journal Article
Open access
AAAmir Akhgari
Amir Akhgari
BBBikash Baral
Bikash Baral
AKArina Koroleva
Arina Koroleva
VSVilja Siitonen
Vilja Siitonen
DFDavid Fewer
David Fewer
MMMikko Metsä-Ketelä
Mikko Metsä-Ketelä
Actinomycetes are important producers of pharmaceuticals and industrial enzymes. However, wild type strains require laborious development prior to industrial usage. Here we present a generally applicable reporter-guided metabolic engineering tool based on random mutagenesis, selective pressure, and single-cell sorting. We developed fluorescence-activated cell sorting (FACS) methodology capable of reproducibly identifying high-performing individual cells from a mutant population directly from liquid cultures. Actinomycetes are an important source of catabolic enzymes, where product yields determine industrial viability. We demonstrate 5-fold yield improvement with an industrial cholesterol oxidase ChoD producer Streptomyces lavendulae to 20.4 U g-1 in three rounds. Strain development is traditionally followed by production medium optimization, which is a time-consuming multi-parameter problem that may require hard to source ingredients. Ultra-high throughput screening allowed us to circumvent medium optimization and we identified high ChoD yield production strains directly from mutant libraries grown under preset culture conditions. Genome-mining based drug discovery is a promising source of bioactive compounds, which is complicated by the observation that target metabolic pathways may be silent under laboratory conditions. We demonstrate our technology for drug discovery by activating a silent mutaxanthene metabolic pathway in Amycolatopsis. We apply the method for industrial strain development and increase mutaxanthene yields 9-fold to 99 mg l-1 in a second round of mutant selection. In summary, the ability to screen tens of millions of mutants in a single cell format offers broad applicability for metabolic engineering of actinomycetes for activation of silent metabolic pathways and to increase yields of proteins and natural products.

4 February 2026 in Nature Communications
Verified
Journal Article
Open access
PDF file
AKArina Koroleva
Arina Koroleva
EAErika Artukka
Erika Artukka
KYKeith Yamada
Keith Yamada
SNSean A. Newmister
Sean A. Newmister
RHRalph J. Harte
Ralph J. Harte
MMMikko Metsä-Ketelä
Mikko Metsä-Ketelä
Doxorubicin, a widely used chemotherapy drug, is produced by Streptomyces peucetius ATCC27952. The biosynthesis relies on the cytochrome P450 monooxygenase DoxA, which catalyzes three consecutive late-stage oxidation steps. However, conversion from daunorubicin to doxorubicin is inefficient, necessitating semi-synthetic industrial manufacturing. Here, we address key limitations in DoxA catalysis. We identify the natural redox partners ferredoxin Fdx4 and ferredoxin reductase FdR3 by transcriptomic analysis. We discovered the vicinal oxygen chelate family protein DnrV to prevent product inhibition by binding doxorubicin. Structural analysis of DoxA and density functional theory (DFT) calculations reveal that inefficient C14 hydroxylation results from the unfavorable anti-conformation of the methyl ketone side chain of daunorubicin. We harness these advances for rational strain engineering, leading to an 180% increase in doxorubicin yields and an improved production profile. This study provides singular insights into enzymatic constraints in anthracycline biosynthesis and facilitates cost-effective manufacturing to meet the growing global demand for doxorubicin.

5 August 2025 in ChemRxiv
Verified
Preprint
Open access
PDF file
HBHannah A. Boesger
Hannah A. Boesger
EFEmma Fang
Emma Fang
RHRalph J. Harte
Ralph J. Harte
AKArina Koroleva
Arina Koroleva
TTTaylan Tunckanat
Taylan Tunckanat
DSDavid Sherman
David Sherman
Doxorubicin, a glycosylated type II PKS-derived natural product first isolated from Streptomyces peucetius is a widely prescribed anticancer medicine and cytotoxic agent. It is also the final oxidation product of DoxA, a cytochrome P450 that catalyzes three sequential C–H oxidation reactions at the C13 and C14 positions on deoxy-daunorubicin leading to doxorubicin. A key limitation of in vitro P450 biocatalysis with anthracycline substrates is the rapid reductive de-glycosylation in the presence of electron donors like NADPH and ferredoxin reductase leading to inactive aglycones. This undesired reaction derails late-stage oxidative functionalization of anthracycline derivatives for clinical development. Recently, we demonstrated that DnrV, a previously uncharacterized vicinal oxygen chelate (VOC) protein in the doxorubicin BGC, prevents reductive activation thereby mitigating the cellular redox stress and metabolite destruction associated with redox cycling. In this study, we employed biochemical, biophysical, and structural methods to elucidate the molecular basis of DnrV function. Our analyses revealed that DnrV is a multifunctional protein that simultaneously modulates the redox characteristics of the bound anthracycline and induces catalytic rate enhancement of the iterative cytochrome P450 DoxA. These are novel functions of the ancient VOC protein family, representing a new functional class we term REdox-Associated CytoToxin binding protein (REACT). Homologues of DnrV from non-anthracycline BGCs display similar redox-protective activity, and some extend this function to the bacterial metabolite menadione. These findings establish REACTs as a conserved family of multifunctional proteins that modulate quinone redox behavior and promote oxidative tailoring of redox-active natural products.

26 March 2026 in ChemRxiv
Verified
Preprint
Open access
HBHannah A. Boesger
Hannah A. Boesger
EFEmma Fang
Emma Fang
RHRalph J. Harte
Ralph J. Harte
AKArina Koroleva
Arina Koroleva
TTTaylan Tunckanat
Taylan Tunckanat
DSDavid Sherman
David Sherman
Redox-mediated chemistry is central to both the biosynthesis and cytotoxicity of many natural products, yet how microbes balance these processes remains poorly understood. Here, we uncover a conserved mechanism that coordinates three redox-mediated processes in secondary metabolite biosynthesis: self-protection, prevention of substrate degradation, and late-stage biocatalysis. Using the antitumor antibiotic doxorubicin as a model system, we show that the Vicinal Oxygen Chelate (VOC) protein DnrV prevents reactive oxygen species formation and substrate degradation while promoting P450 catalysis. We expand this paradigm to a conserved family of VOC-fold proteins, REdox-Associated CytoToxin binding proteins (REACT), found across bacteria, fungi, and plants. REACT represents a multifunctional protein class that balances antibiotic assembly, self-protection, and prevention of metabolite destruction, providing a foundational understanding of production of redox-active natural products.

19 November 2026 in Science
Verified
Journal Article
Closed access
HBHannah A. Boesger
Hannah A. Boesger
EFEmma Fang
Emma Fang
RWRongbin Wang
Rongbin Wang
RHRalph J. Harte
Ralph J. Harte
AKArina Koroleva
Arina Koroleva
DSDavid Sherman
David Sherman
Redox-mediated chemistry is central to both the biosynthesis and cytotoxicity of many natural products, yet how microbes balance these processes remains poorly understood. Here, we uncover a conserved mechanism that coordinates three redox-mediated processes in secondary metabolite biosynthesis: self-protection, prevention of substrate degradation, and late-stage biosynthesis. Using the antitumor antibiotic doxorubicin as a model system, we show that the vicinal oxygen chelate (VOC) protein DnrV prevents reactive oxygen species formation and substrate degradation while promoting P450 catalysis. We expand this paradigm to a conserved family of VOC-fold proteins, redox-associated cytotoxin-binding proteins (REACT), found across bacteria, fungi, and plants. REACT represents a multifunctional protein class that balances antibiotic assembly, self-protection, and prevention of metabolite destruction, providing a foundational understanding of production of redox-active natural products.

13 May 2026 in mBio
Verified
Journal Article
Open access
KYKeith Yamada
Keith Yamada
AKArina Koroleva
Arina Koroleva
HTHeli Tirkkonen
Heli Tirkkonen
VSVilja Siitonen
Vilja Siitonen
MLMitchell Laughlin
Mitchell Laughlin
MMMikko Metsä-Ketelä
Mikko Metsä-Ketelä
Microbial predators obtain energy from killing other living cells. Streptomyces are soil bacteria that are known to produce numerous catabolic enzymes and antimicrobial compounds to defend against competing organisms. Here, we demonstrate that Streptomyces are predatory bacteria that prey on Saccharomyces cerevisiae . Time-lapse fluorescence microscopy and scanning electron microscopy revealed that predation is initiated by physical contact between Streptomyces lavendulae YAKB-15 and yeast cells. Comparative transcriptomics indicated that the interaction triggered the production of numerous extracellular catabolic enzymes and natural products, while delaying morphological development. Proteomics and enzyme assays confirmed co-culture-dependent production of carbohydrate-active enzymes (CAZymes), including various glucanases, mannosidases, and chitinases, which degraded the yeast cell wall. Streptomyces lavendulae YAKB-15 destabilized yeast cell membranes through the production of two polyene antifungal agents, pentamycin and filipin III. We found that the bioactivity was enhanced by cell-associated cholesterol oxidase ChoD, putatively by modulating sterol extraction kinetics. Metabolomic analyses suggest Streptomyces assimilates yeast cell sterols as nutrients. Furthermore, we observed the depletion of yeast-derived phosphatidylcholine and phosphatidylethanolamine lipids, which points to their consumption. We show that yeast predation is a common phenomenon in Streptomyces , which changes the paradigm of how these bacteria should be considered in the soil microbiome ecosystem. IMPORTANCE: Soil is a rich environment for microbes, where they compete for space and resources. Streptomyces bacteria are well known for their ability to synthesize natural products, particularly antibiotics, that are used in chemical defense against competing microbes. Here, we show that Streptomyces are, in fact, predatory bacteria. Upon encountering yeast cells, Streptomyces initiate the production of numerous enzymes that digest the cell wall and cell membrane. In addition, the interaction triggers the production of natural products that destabilize the yeast cell membrane. Collectively, these actions lead to the death of yeast cells and release of cellular building blocks that Streptomyces can use as nutrients. The work fundamentally shifts the paradigm of how Streptomyces are perceived within the soil microbiome ecosystem.